Fernando Ventureira, CEO of Stratence Partners, will be in Singapore for the Asian Pricing Summit and is open to connecting with peers and executives during those days.

Pricing is no longer a function. It is a structural driver of performance. Discover how leading organizations are transforming pricing into a sustainable competitive edge.

IT companies lose up to 12% of EBIT due to fragmented commercial decisions. Learn how structured Commercial Transformation restores control, transparency and profitability.

Pricing is no longer a function. It is a structural driver of performance. Discover how leading organizations are transforming pricing into a sustainable competitive advantage.

Financial Services organizations lose up to 12% of EBIT due to fragmented commercial decisions. Discover how an integrated Commercial Transformation approach restores control, transparency, and profitability.

Today at CIPMI London 2026, Fernando Ventureira, CEO of Stratence Partners, shared how organizations can move from fragmented intelligence to structured commercial decisions that protect margin and drive performance.

This week, Stratence Partners CEO Fernando Ventureira will be in London at CIPMI 2026, addressing how organizations translate strategy and intelligence into structured executive decisions.

Next week, Stratence Partners CEO Fernando Ventureira will be in London at CIPMI 2026, addressing how organizations translate strategy and intelligence into structured executive decisions.

Industrial Manufacturing is no longer defined by operational excellence alone. Discover how leading organizations are achieving measurable EBIT impact through Commercial Transformation and AI Powered decision systems.

Insights from the 9th Pricing & Revenue Management Summit in Berlin, where Stratence Partners shared perspectives on how organizations are integrating strategy, pricing economics and sales execution into structured Commercial Transformation frameworks.

Stratence Partners participates in the Andersen Consulting Global Partners Meeting in Las Vegas, represented by CEO Fernando Ventureira.

At EPA Amsterdam 2026, Fernando Ventureira, CEO of Stratence Partners, presented two sessions addressing critical challenges for pharmaceutical and MedTech companies: mastering Gross to Net complexity and embedding AI into commercial decision making. This article summarizes the key insights on how organizations can transform pricing, access, and commercial execution into a unified performance system.

A moment captured at EPA 2026 in Amsterdam reflects the importance of teamwork across Andersen and Stratence Partners leadership, bringing together expertise from Tax, Commercial Transformation and Healthcare industry strategy.

Life & Annuity carriers are facing record demand — but volume is masking structural inefficiencies. This paper explores how business-driven AI enables scalable, profitable growth beyond linear expansion models.

Fernando Ventureira will be in Amsterdam next week. Coffee or dinner with local business leaders.

Ahead of EPA 2026, Stratence Partners is hosting a closed-door VIP Dinner for selected VP and C-level executives in Pricing, Market Access, Commercial and Finance governance.

Animal Health companies face structural margin erosion from fragmented pricing, opaque gross-to-net dynamics, and misaligned execution. AI-Powered Commercial Transformation is no longer optional — it is strategic.

EPA 2026: From Attendance to Impact The World Evidence, Pricing & Access Congress remains Europe’s most relevant gathering for senior leaders in pricing, market access, HEOR, and commercial strategy. But attendance alone does not create value. Impact comes from addressing structural weaknesses that silently erode EBIT year after year. As a global firm specialized in Commercial Transformation, AI Powered, Stratence Partners returns to EPA 2026 with two focused executive sessio

Commercial Transformation is not about isolated pricing initiatives. It is about structurally aligning strategy, pricing economics and commercial execution into one integrated, governed and AI Powered system that delivers sustainable competitive advantage.

In Medical Devices, margin erosion rarely comes from innovation. It comes from fragmented commercial governance. Stratence Partners explains how Commercial Transformation, AI Powered, restores structural control and delivers measurable EBIT impact within year one.